Dr. Palumbo on Significance of Daratumumab Triplet in Multiple Myeloma

Antonio Palumbo, MD
Published: Monday, Aug 22, 2016


Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.

Based on phase III findings of the CASTOR trial that explored this regimen, the triplet creates a new treatment paradigm for patients. While R-CHOP has been a standard treatment for patients with lymphomas, daratumumab will likely be the equivalent for patients with myeloma, Palumbo explains.

Next steps involve exploring and ultimately moving this type of regimen into earlier courses of disease in hopes of doubling remission rates, he adds.

Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the impact the triplet regimen of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone will have on the field of multiple myeloma.

Based on phase III findings of the CASTOR trial that explored this regimen, the triplet creates a new treatment paradigm for patients. While R-CHOP has been a standard treatment for patients with lymphomas, daratumumab will likely be the equivalent for patients with myeloma, Palumbo explains.

Next steps involve exploring and ultimately moving this type of regimen into earlier courses of disease in hopes of doubling remission rates, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x